Artrya's First Commercial Agreement in Australia

Artrya Limited (ASX: $AYA) has initiated its first commercial agreement in Australia with The Cardiac Centre NSW for the use of its Salix® Coronary Anatomy software. This 12-month agreement marks a significant milestone for Artrya as it enters the Australian market, with the software set to be utilized across four specialist cardiac centres in Wollongong, Shellharbour, Bowral, and Nowra. The agreement is expected to generate the company's first revenues in Q4 FY24 through a subscription model to the Salix platform.

Executive Commentary on the Agreement

Artrya CEO Mathew Regan expressed his satisfaction with the commercial agreement, highlighting the company's advanced technology platform for the detection, diagnosis, and care of coronary artery disease. He emphasized the significance of this agreement in validating their market entry strategy and the potential for expansion across New South Wales and other Australian states. Dr. Barry Elison, senior cardiovascular imaging specialist at The Cardiac CT Centre NSW, and Dr. Jorge Moragues, cardiologist and cardiac imaging specialist, praised the incorporation of Salix into their diagnostic process, citing its ability to improve patient care and the diagnostic workflow of coronary artery disease.

Summary of Artrya's Commercial Agreement and Outlook

Artrya's commercial agreement with The Cardiac Centre NSW marks a pivotal step in the company's expansion into the Australian market. The agreement, which involves the use of Salix® Coronary Anatomy software across four specialist cardiac centres, is expected to generate the company's first revenues in Q4 FY24. The CEO's commentary underscores the potential for further expansion across New South Wales and beyond. With heart disease being the leading cause of death in Australia, Artrya's AI-driven Salix platform presents a significant advancement in coronary heart diagnosis and care, with the potential to save costs and minimize patient readmissions. The positive reception from the specialists at The Cardiac Centre NSW further validates the potential impact of Salix in improving patient care and diagnostic accuracy.